Insider buying last 90 days
No open-market insider purchases were filed for NRIX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every NRIX insider filing, plotted on the chart in Gekko.Open NRIX in Gekko
NASDAQ: NRIX
Nurix Therapeutics (NRIX) Stock Analysis & Forecast
Oct 12 close
$22.16−0.19 (−0.9%)
Gekko Brief
AI summaryOct 12 closeThis week Nurix Therapeutics reported third quarter 2026 results, with earnings and revenues surpassing estimates and a narrower loss per share compared to a year-ago loss of $1.03 per share. The company also dosed the first patient in the registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib, and separately enrolled the first patient in a Phase 1b/2 study combining bexobrutideg with venetoclax in chronic lymphocytic leukemia, part of its collaboration with Roche. Alongside the clinical updates, Nurix announced a second two-year extension of its oncology research collaboration with Gilead Sciences, maintaining a potential $1.3 billion agreement, and noted a $7 million milestone payment from its Pfizer partnership, bringing total payments from that collaboration to $82 million.
NRIX closed at $22.16, down 0.9% on the day, sitting between its 50-day average of $25.16 and 200-day average of $19.70. The one-month return stands at -11.7% while the six-month return is 39.3% and the one-year return is 104.1%. The GekkoIndex reads 71.6, placing the stock in the Buying zone, up 3.2 over five days. The price sits 22.7% below Gekko Fair Value of $28.67.
No confirmed earnings date is on the calendar following the 9 July 2026 report, which beat estimates in 5 of the last 8 quarters and produced a -5.1% reaction. Over the next 20 trading days, seasonality from this point in the calendar has averaged +15.2% across 5 years, rising in 4 of them. No insider, Congress, or unusual options activity appears in the current windows. Analyst consensus from 5 firms shows 4 buy ratings and 1 hold, with a consensus target of $33.93.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Nurix Therapeutics price vs fair value
Close $22.16200-day averageGekko Fair Value $28.67
Nurix Therapeutics quick facts
- Market cap
- $2.30B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$3.46
- Revenue, TTM
- $36.77M
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 1.82
- Volume
- 2.12M avg 1.51M
- 1-year return
- +104.1%
- Typical daily move
- ±4.6%
- Typical 20-day move
- ±12.8%
- 50-day average
- $25.16
- 200-day average
- $19.70
- Next earnings
- —
- Shares outstanding
- 103.8M
Nurix Therapeutics swing-trade checklist
Nurix Therapeutics scores 3 supportive, 1 mixed and 0 headwinds across the 4 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed0 headwinds
- Trendmixed
Averages disagree
Close $22.16 sits between the 50-day ($25.16) and 200-day ($19.70) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
71.6, Buying
Reading 71.6 is in the Buying zone.
See the GekkoIndex - Fair valuesupportive
22.7% below
Price is 22.7% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskno data
No data
No confirmed report date on the calendar.
See earnings - Seasonalitysupportive
+15.2% on average
From this point in the calendar, the next 20 trading days averaged +15.2% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Nurix Therapeutics stock chart and price history
Nurix Therapeutics closed at $22.16 on Oct 12, 2026, +104.1% over the past year, inside a 52-week range of $9.00 to $28.23.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −11.7%
- 3 months
- −3.6%
- 6 months
- +39.3%
- 1 year
- +104.1%
The full NRIX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open NRIX in Gekko
Follow Nurix Therapeutics through every session
Put NRIX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track NRIX in GekkoFree for 7 days. No credit card required.
About Nurix Therapeutics
Nurix Therapeutics works on medicines still in clinical testing, built around small molecules and antibodies meant to treat cancer, inflammatory disorders, and related illnesses. Its pipeline includes degrader compounds aimed at Bruton's tyrosine kinase for B-cell cancers and autoimmune disease, a CBL-B inhibitor being studied for immuno-oncology use, and a separate program targeting IRAK4 for rheumatoid arthritis and other inflammatory conditions. Several of these candidates have reached mid-stage human trials, while others remain in earlier testing phases.
Rather than operating alone, the company pairs its own research with outside partners, holding joint development and commercialization arrangements with Gilead Sciences, Sanofi, and Pfizer that cover a number of its drug candidates. This collaborative structure allows costs and potential future revenue from several programs to be shared across these larger pharmaceutical partners rather than resting solely with Nurix.
The company is based in Brisbane, California, and traces its incorporation back to 2009, having operated earlier under the name Nurix Inc. before adopting its current name in 2018. Its shares trade on the NASDAQ under the ticker NRIX.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- nurixtx.com
Nurix Therapeutics GekkoIndex: the smart money zone
Nurix Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 71.6, in the Buying zone, up 3.2 points over five sessions.
71.6Buying
Up 3.2 points over five sessions, from the Accumulation zone.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying (current zone) | 24 | −2.2% | +4.8% | ||
| Accumulation | 230 | 0.0% | +1.6% | ||
| Neutral | 374 | +1.9% | +6.5% | ||
| Distribution | 52 | +2.3% | +8.3% | ||
| Selling | 2 | Too few readings yet | |||
Average NRIX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Buying readings averaged +3.1% over 20 days. Past behaviour doesn’t guarantee future results.
Buying zone: Smart money likely accumulating heavily. About the five zones →
See every daily GekkoIndex reading plotted over the NRIX price, zone by zone.Track NRIX in Gekko
Is Nurix Therapeutics stock overvalued? Gekko Fair Value
Nurix Therapeutics trades 22.7% below Gekko Fair Value of $28.67, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Nurix Therapeutics shares are worth, recalculated every trading day.
$28.67
Gekko Fair Value, Oct 10, 2026
22.7% Undervalued
At the end of Aug 2026 the price was 15.0% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open NRIX in Gekko
Nurix Therapeutics insider and Congress trading
No open-market insider purchases were filed for Nurix Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in NRIX were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for NRIX, plotted on the chart in Gekko.Open NRIX in Gekko
Buybacks
Nurix Therapeutics has been buying back its own shares.
- Bought back, quarter ended Aug 31, 2024
- $15K
- As a share of market cap
- 0.00%
From company filings.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds NRIX.
0added1opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Nurix Therapeutics earnings: next date and track record
Nurix Therapeutics beat the EPS estimate in 5 of its last 8 reports, moving 4.8% on average across the report.
5 of 8reports beat the EPS estimate
±4.8%average move across the report
2 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 9, 2026 | −$0.81 est −$0.73 | $9.04M est $15.29M | −5.1% |
| Apr 8, 2026 | −$0.79 est −$0.83 | $6.25M est $14.25M | −0.7% |
| Jan 28, 2026 | −$0.82 est −$0.92 | $13.58M est $13.40M | −9.4% |
| Oct 9, 2025 | −$1.03 est −$0.84 | $7.89M est $12.26M | −2.2% |
| Jul 9, 2025 | −$0.52 est −$0.71 | $44.06M est $17.51M | +3.8% |
| Apr 8, 2025 | −$0.67 est −$0.76 | $18.45M est $15.82M | −1.2% |
| Jan 28, 2025 | −$0.75 est −$0.67 | $13.28M est $14.78M | −0.8% |
| Oct 11, 2024 | −$0.67 est −$0.71 | $12.59M est $12.81M | +15.1% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Nurix Therapeutics stock forecast and analyst price targets
Analysts’ average 12-month price target for Nurix Therapeutics is $33.93, +53.1% from the last close, from 5 firms rating the stock in the last 90 days.
$33.93consensus 12-month target, +53.1% from the last close
Now $22.16Avg $33.93
Low $25High $38
Each firm’s latest rating in the last 90 days: 5 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 1 | Wells Fargo | $25 | +12.8% |
| Aug 10 | RBC Capital | $36 | +62.5% |
| Aug 4 | Needham | $34 | +53.4% |
| Jul 28 | Morgan Stanley | $38 | +71.5% |
| Jul 27 | Morgan Stanley | $38 | +71.5% |
+4.8%average 20-day move after past Buying readings
+15.2%average move over the next 20 trading days in the last 5 years
±4.6%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Nurix Therapeutics seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Nurix Therapeutics averaged +15.2% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +2.6% | 4 of 5 |
| Next 10 trading days | −0.2% | 4 of 5 |
| Next 15 trading days | +12.8% | 4 of 5 |
| Next 20 trading days | +15.2% | 4 of 5 |
| Next 30 trading days | +18.2% | 4 of 5 |
For scale, NRIX’s typical 20-trading-day move in either direction is about 12.8%.
Nurix Therapeutics market cap and key statistics
Nurix Therapeutics’s market cap is $2.30B and revenue of $36.77M over the last twelve months.
Valuation
- Market cap
- $2.30B
- EPS, TTM
- −$3.46
- Gekko Fair Value
- $28.67
Trading
- Volume
- 2.12M
- Avg volume, 20 days
- 1.51M
- 52-week high
- $28.23
- 52-week low
- $9.00
- Shares outstanding
- 103.8M
Financials
- Revenue, TTM
- $36.77M
- Profit margin
- 0%
- Return on equity
- -80.3%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 1.82
- Typical daily move
- ±4.6%
- Typical 20-day move
- ±12.8%
Nurix Therapeutics stock news this week
Coverage of Nurix Therapeutics this week reads positive: 6 positive, 1 neutral and 0 negative headlines.
- Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass EstimatesZacks Investment Research, Oct 12
- Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewsWire, Oct 12
- Nurix Therapeutics (NRIX) Starts New CLL Trial, Is The 11% Discount Warranted?Simply Wall Street, Oct 9
- Should Collaboration Extension Require Action From Nurix Therapeutics (NRIX) Investors?Simply Wall Street, Oct 8
- Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic LeukemiaInvesting News Network, Oct 7
- Nurix Therapeutics Enrolls First Patient in Phase 1b/2 Study of Bexobrutideg Combined with Venetoclax in CLLQuiver Quantitative, Oct 7
Nurix Therapeutics peers
Nurix Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 25.5% below |
| GILDGilead Sciences | Neutral | 4.2% above |
| MRNAModerna | Neutral | 62.7% above |
| NTRANatera | Neutral | 10.3% above |
| IQVIQVIA | Neutral | 8.4% above |
| UTHRUnited Therapeutics | Neutral | 14.4% below |
A peer links to its own page where one exists.
Nurix Therapeutics stock FAQ
What is Nurix Therapeutics’s market cap?
Nurix Therapeutics’s market cap is $2.30B at the Oct 12, 2026 close of $22.16, with 103.8M shares outstanding.
What is the Nurix Therapeutics stock forecast?
The consensus analyst 12-month price target for Nurix Therapeutics is $33.93, +53.1% from the last close. Of the 5 firms that rated the stock in the last 90 days, 4 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Nurix Therapeutics stock overvalued or undervalued?
On Gekko’s estimate Nurix Therapeutics is undervalued: the Oct 12, 2026 close of $22.16 is 22.7% below Gekko Fair Value of $28.67. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
What is Nurix Therapeutics’s 52-week high and low?
Nurix Therapeutics’s 52-week high is $28.23 and its 52-week low is $9.00; it closed at $22.16 on Oct 12, 2026, +104.1% over the past year. Over the last five years the shares peaked at $36.24 on Oct 27, 2021.
Is Nurix Therapeutics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 4 items with data read as supportive (gekkoindex, fair value and seasonality), 1 as mixed (trend). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Nurix Therapeutics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.